clinical trial · NCT04908202
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Bristol-Myers Squibb·phase3·active not recruiting·n = 670
Psoriatic ArthritisDeucravacitinibPlacebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.
started
Jul 13, 2021
primary completion
Sep 5, 2024
completion
Jun 10, 2027
last updated
Apr 23, 2026
official title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol